More recently, B7-H3 has been successfully co-targeted by B7-H3-CD70 tandem CARs (Tan-CAR) in non-glioma PDX models, improving preclinical response compared to single targeting of either antigen [128]. This evidence concerns the gene CD276 and central nervous system cancer.